KR20240018523A - 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제 - Google Patents
다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제 Download PDFInfo
- Publication number
- KR20240018523A KR20240018523A KR1020237045200A KR20237045200A KR20240018523A KR 20240018523 A KR20240018523 A KR 20240018523A KR 1020237045200 A KR1020237045200 A KR 1020237045200A KR 20237045200 A KR20237045200 A KR 20237045200A KR 20240018523 A KR20240018523 A KR 20240018523A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- weight
- less
- compound represented
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2021-096206 | 2021-06-08 | ||
| JP2021096206 | 2021-06-08 | ||
| PCT/JP2022/023076 WO2022260064A1 (ja) | 2021-06-08 | 2022-06-08 | ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240018523A true KR20240018523A (ko) | 2024-02-13 |
Family
ID=84426023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237045200A Pending KR20240018523A (ko) | 2021-06-08 | 2022-06-08 | 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제 |
Country Status (12)
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011136269A1 (ja) | 2010-04-28 | 2011-11-03 | アステラス製薬株式会社 | テトラヒドロベンゾチオフェン化合物 |
| WO2012006475A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| WO2013062065A1 (ja) | 2011-10-27 | 2013-05-02 | アステラス製薬株式会社 | アミノアルキル置換n-チエニルベンズアミド誘導体 |
| WO2014003153A1 (ja) | 2012-06-28 | 2014-01-03 | 協和発酵キリン株式会社 | 置換アミド化合物 |
| WO2014142273A1 (ja) | 2013-03-13 | 2014-09-18 | 中外製薬株式会社 | ジヒドロピリダジン-3,5-ジオン誘導体 |
| WO2016026822A1 (en) | 2014-08-18 | 2016-02-25 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| WO2016039458A1 (ja) | 2014-09-12 | 2016-03-17 | 中外製薬株式会社 | ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬 |
| WO2018034883A1 (en) | 2016-08-15 | 2018-02-22 | Eli Lilly And Company | Condensed thiophene derivatives useful as napi-iib inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9499553B2 (en) * | 2013-03-13 | 2016-11-22 | Chugai Seiyaku Kabushiki Kaisha | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same |
| WO2019060604A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE MEDICINE |
| US12097204B2 (en) * | 2018-09-03 | 2024-09-24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof |
-
2022
- 2022-06-08 WO PCT/JP2022/023076 patent/WO2022260064A1/ja not_active Ceased
- 2022-06-08 KR KR1020237045200A patent/KR20240018523A/ko active Pending
- 2022-06-08 US US18/567,435 patent/US20240293402A1/en active Pending
- 2022-06-08 AU AU2022288895A patent/AU2022288895A1/en active Pending
- 2022-06-08 CA CA3221186A patent/CA3221186A1/en active Pending
- 2022-06-08 IL IL309056A patent/IL309056A/en unknown
- 2022-06-08 EP EP22820243.8A patent/EP4353233A4/en active Pending
- 2022-06-08 MX MX2023014507A patent/MX2023014507A/es unknown
- 2022-06-08 CN CN202280041019.3A patent/CN117460511A/zh active Pending
- 2022-06-08 TW TW111121208A patent/TW202317118A/zh unknown
- 2022-06-08 JP JP2023527886A patent/JPWO2022260064A1/ja active Pending
- 2022-06-08 BR BR112023023708A patent/BR112023023708A2/pt unknown
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011136269A1 (ja) | 2010-04-28 | 2011-11-03 | アステラス製薬株式会社 | テトラヒドロベンゾチオフェン化合物 |
| WO2012006475A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| WO2013062065A1 (ja) | 2011-10-27 | 2013-05-02 | アステラス製薬株式会社 | アミノアルキル置換n-チエニルベンズアミド誘導体 |
| WO2014003153A1 (ja) | 2012-06-28 | 2014-01-03 | 協和発酵キリン株式会社 | 置換アミド化合物 |
| WO2014142273A1 (ja) | 2013-03-13 | 2014-09-18 | 中外製薬株式会社 | ジヒドロピリダジン-3,5-ジオン誘導体 |
| WO2016026822A1 (en) | 2014-08-18 | 2016-02-25 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| WO2016039458A1 (ja) | 2014-09-12 | 2016-03-17 | 中外製薬株式会社 | ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬 |
| WO2018034883A1 (en) | 2016-08-15 | 2018-02-22 | Eli Lilly And Company | Condensed thiophene derivatives useful as napi-iib inhibitors |
Non-Patent Citations (9)
| Title |
|---|
| "Chapter 1: Definition and classification of CKD" Kidney Int. Suppl., 2013, 3(1), 19-62. |
| Forster IC et al., Mol Aspects Med., 2013, 34(2-3), 386-395. |
| Hruska, KA et al., Kidney Int., 2008, 74(2), 148-157. |
| Lederer E et al., Eur. J. Physiol., 2019, 471(1), 137-148. |
| Levey, AS et al., Kidney Int., 2005, 67(6), 2089-2100. |
| Miyamoto, K et al., J. Pharm. Sci., 2011, 100(9), 3719-3730. |
| Ritter, CS et al., Clin. J.Am.Soc.Nephrol.2016, 11(6), 1088-1100. |
| Sabbagh, Y et al., J. Am. Soc. Nephrol., 2009, 20(11), 2348-2358. |
| 발명추진협회 공개기보 제2017-501666 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117460511A (zh) | 2024-01-26 |
| MX2023014507A (es) | 2024-01-26 |
| EP4353233A1 (en) | 2024-04-17 |
| BR112023023708A2 (pt) | 2024-01-30 |
| AU2022288895A1 (en) | 2024-01-18 |
| US20240293402A1 (en) | 2024-09-05 |
| IL309056A (en) | 2024-02-01 |
| TW202317118A (zh) | 2023-05-01 |
| WO2022260064A1 (ja) | 2022-12-15 |
| JPWO2022260064A1 (cg-RX-API-DMAC7.html) | 2022-12-15 |
| EP4353233A4 (en) | 2025-06-25 |
| CA3221186A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Almansa et al. | Co-Crystal of Tramadol hydrochloride–Celecoxib (CTC): a novel API–API co-crystal for the treatment of pain | |
| JP4633469B2 (ja) | 経口固形医薬 | |
| HK1213814A1 (zh) | 双氯芬酸制剂和使用方法 | |
| UA59383C2 (uk) | Композиція зипразидону (варіанти), спосіб лікування психозів та спосіб одержання великих кристалів зипразидону | |
| KR20140069297A (ko) | N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물 | |
| JP4805234B2 (ja) | 経口固形医薬 | |
| EP3290037A1 (en) | Pharmaceutical composition for oral administration | |
| JP7821749B2 (ja) | アカラブルチニブマレイン酸塩剤形 | |
| CN120091817A (zh) | 奥比塞曲匹与依折麦布组合治疗和固定剂量药物组合物 | |
| WO2016001208A1 (en) | Stable pharmaceutical compositions in the form of immediate release tablets | |
| TWI728156B (zh) | 含有胺甲蝶呤之膜衣錠 | |
| WO2021216545A1 (en) | Oral solid meloxicam formulations for the treatment of acute pain | |
| EP4353233A1 (en) | Preparation containing dihydropyridazine-3,5-dione derivative | |
| HK40104119A (en) | Formulation containing dihydropyridazine-3,5-dione derivative | |
| JP7820568B2 (ja) | 溶出性及び打錠性に優れた製剤 | |
| JP6112765B2 (ja) | ロキソプロフェンナトリウム及びdl−メチルエフェドリン塩酸塩を含有する固形製剤 | |
| Munnangi | Advancing Pharmaceutical Manufacturing: Innovative Applications of Hot Melt Extrusion for the Preparation of Drug Complexes and Fixed Dose Combination Immediate Release Formulation with Diverse Crystalline Properties | |
| WO2017019862A1 (en) | Combination formulation of laquinimod and glatiramer acetate with amino acids | |
| HK40051811A (en) | Diclofenac formulations and methods of use | |
| Ely | Extraction, Characterization, and Tablet Formulation of the Mitragyna Speciosa Kratom Plant | |
| EP4059504A1 (en) | Drug substance of lemborexant and medicinal composition comprising same | |
| BR112015018952B1 (pt) | Composições farmacêuticas contendo dexcetoprofeno e tramadol, seu método de fabricação e seu uso | |
| CN118201934A (zh) | 伊努帕地南盐酸盐、药物组合物及其使用方法 | |
| KR20160079178A (ko) | 실로도신을 포함하는 고형 경구제제 | |
| JP6110589B2 (ja) | ロキソプロフェンナトリウムとクレマスチンフマル酸塩を含有する固形製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231228 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250605 Comment text: Request for Examination of Application |